FDA
-
-
-
-
-
-
-
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease wi
-
-
-
-
-
-
-
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradi
-
-
-
-
-
-
-
FDA approves accord Biopharma's Immgolis, a biosimilar to Simponi
-
-
-
-
-
-
-
Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
-
-
-
-
-
-
-
Johnson & Johnson to acquire medical device firm Atraverse Medical
-
-
-
-
-
-
-
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
-
-
-
-
-
-
-
Morgan Stanley stays Overweight on Johnson & Johnson (JNJ) following 'expected positive' Ico approval
-
323,123 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

